Key Takeaways and Future in Advanced Gastric Cancer Treatment

Opinion
Video

Panelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.

  • What are some key takeaways from this discussion?
  • What will be important to evaluate in future analyses in advanced gastric cancers?
Recent Videos
5 experts in this video
Related Content
Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer

Roman Fabbricatore
March 23rd 2025
Article

Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

Geoffrey Y. Ku, MD
January 18th 2017
Podcast

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer

Russ Conroy
March 17th 2025
Article

Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

ONCOLOGY Staff
March 14th 2025
Article

Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

Russ Conroy
March 7th 2025
Article

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer

Roman Fabbricatore
March 5th 2025
Article

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.